Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorPeking University Cancer Hospital & Institute
About this trial
This is a single-arm, open-label, single-center phase II trial that will enroll 30 patients with limited-stage small-cell lung cancer to evaluate the safety and efficacy of adebrelimab combined with chemoradiotherapy followed by adebrelimab maintenance.
Eligibility criteria
Qualifiers
Age 18-75 years, either sex. Histologically or cytologically confirmed limited-stage small-cell lung cancer (LS-SCLC) defined by Veterans Administration Lung Group (VALG) two-stage system.
Disqualifiers
Prior solid-organ, allogeneic stem-cell or planned transplantation. Immunosuppressive therapy ≤ 14 days before first adebrelimab dose (except intranasal/inhaled corticosteroids or physiological systemic doses equivalent to ≤ 10 mg/day prednisolone).
Trial design
Treatments tested in this trial
- Adebrelimab with concurrent chemoradiotherapy
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
1Peking University Cancer Hospital and Institute100142, BeijingBeijing Municipality, China
Sponsors and collaborators
Peking University Cancer Hospital & Institute
Lead sponsor
Source ClinicalTrials.gov